Skip to main content

Novel Rx

SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

May 10, 2022

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 



The study

Read Article
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritishttps://t.co/5dXe0AdNzE https://t.co/eS4KdaKBmC
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Trends in RA Disability, Despite Biologics Disability claims in the U.S. related to RA were just as common in 2015 as in 1999, a gov't researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.https://t.co/vyyjTbkLN2 https://t.co/D5Eo42P4cw
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

May 04, 2022

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

MedPage Today
May 03, 2022

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.



Over that 17-year period, rates of Medicare

Read Article
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

May 02, 2022

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z
Dr. John Cush @RheumNow( View Tweet )
May 01, 2022
Spanish BIOBADASER registry real world performance of secukinumab in 639 pts w/ #PsA & spondyloarthritis (axSpA, AS, NR axSpA) showed imprved Dz activity at 1 yr & maintained or increased 2 & 3 years. Retention rates best when SEC used 1st biologic https://t.co/MAE3BhLlRg

Dr. John Cush @RheumNow( View Tweet )

Apr 26, 2022
JIA.oligoarticular.jpg

Biologics for JIA? Not So Fast, Say Insurers

MedPage Today
Apr 25, 2022

It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.



Among 54 patients seen at Boston Children's Hospital for newly diagnosed JIA in 2018-2019,

Read Article
Mark your calendars for our next Tuesday Night Rheumatology on 4/26 at 7pm! Speakers will include: Dr. Eric Ruderman Dr. Arthur Kavanaugh Dr. David Liew Dr. Jack Cushhttps://t.co/by1xtmPSZ0You can also find us LIVE on YouTube, Twitter, and Facebook. https://t.co/o633KHx81b
Dr. John Cush @RheumNow( View Tweet )
Apr 25, 2022
Did you missed this past Tuesday Night Rheumatology? We have the playback available now. The PsA Expert panelists included: Dr. Dafna Gladman Dr. Joseph Merola, Dr. Peter Nash, Dr. Christopher Ritchlin, Dr. Jose Scher and Dr. Jack Cush.https://t.co/u5lt2uDoGK https://t.co/lOmN4OoGLi
Dr. John Cush @RheumNow( View Tweet )
Apr 22, 2022
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTXhttps://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK
Dr. John Cush @RheumNow( View Tweet )
Apr 14, 2022
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today
Apr 14, 2022

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
QD Clinic - PsA Lessons from the Clinic Reasons why PsA patient can lose biologic efficacy and what to do about it QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ
Dr. John Cush @RheumNow( View Tweet )
Apr 13, 2022
How long does a good response last to a biologic? How and When to distinguish between flares and intercurrent illness. QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/ZIWQysY5dd https://t.co/RZrS6FfUTV
Dr. John Cush @RheumNow( View Tweet )
Apr 12, 2022
ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR
Dr. John Cush @RheumNow( View Tweet )
Apr 09, 2022
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.




  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez
Dr. John Cush @RheumNow( View Tweet )
Apr 08, 2022
Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6
Dr. John Cush @RheumNow( View Tweet )
Apr 05, 2022
#PsA Biologic initiation was associated with a SMALL drop in NSAIDs (51.1 to 42.5%); glucocorticoids (57.4 to 46.9%) and opioids (38.1 to 33.8%) (Initial vs 12 mos later). Pain Rx use study in 5681 PsA, 2180 AS, & 34,047 RA pts #PsAlways https://t.co/wyrT9CVNq8 https://t.co/8vl7e2a63n
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
×